 |
Biotherapeutics Analytical Summit
March 19, 2012—March 22, 2012
Baltimore, Maryland, USA
8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
March 19, 2012—March 22, 2012
Istanbul, Turkey
CPhI Japan
March 21, 2012—March 23, 2012
Tokyo, Japan
World Companion Diagnostics Summit Europe
March 26, 2012—March 29, 2012
Frankfurt, Germany
9th Annual Controlled Release
March 28, 2012—March 29, 2012
London, United Kingdom
|
|
|
 |
 |
 Microbial colony pickers for large cell-population management
Molecular Devices’s QPix 400 series of microbial colony pickers manages of large, diverse populations of cells. The QPix 400 series, which includes the QPix 400, 450, and 460 models, features the option to simultaneously detect colonies and quantify fluorescent markers. This prescreening step enables the colonies of interest to be objectively identified and selected. The specific colony can then be chosen using highly accurate robotics and organism-specific colony-picking pins.
The device's application-driven software contains tools to track sample histories throughout a workflow. Its applications include areas such as protein expression, biofuel research, enzyme evolution, phage display, DNA sequencing and library generation and management. The QPix 460 is the most advanced system of the QPix 400 range, offering automation of the entire workflow from sampling and spreading onto bioassay plates. Additional features include imaging, analysis, and transferring selected colonies to up to 140 destination plates in two stacker lanes, thereby shortening timelines and increasing overall lab productivity. |
|
|
 |
|
AstraZeneca filed a lawsuit against FDA in the United States District Court for the District of Columbia to overturn the FDA's Mar. 7, 2012 denial of Citizen Petitions filed by AstraZeneca with regard to the Seroquel (quetiapine fumarate) tablets and Seroquel XR extended-release tablets, a treatment for bipolar disorder. AstraZeneca seeks an injunction which would bar FDA from granting final marketing approval of generic quetiapine until Dec. 2, 2012, when regulatory exclusivity expires on important clinical trial data, or at least until a federal court has a meaningful opportunity to review imminent FDA action regarding the pending generic marketing applications. Read More
Advertisement:
8 Ways to Reduce Tablet Manufacturing Costs
Are you working with a reduced budget for 2012? Want to learn how to get more and spend less? In an effort to help our customers get the most from their budgets, we put together this valuable list complete with tips, products, and video.  Click here now for access to the exclusive details! |
The biotechnology company Biocon and Pfizer have ended their alliance to commercialize Biocon's biosimilar versions of Insulin and Insulin analog products. The companies have agreed that, due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently. Read More
Advertisement:
Podcast -  Process Validation for Sterile Manufacturing
Join William (JR) Humbert, the Validation Manager at Cook Pharmica, as he discusses the 2011 FDA Guidance for the Industry, Process Validation: General Principles and Practices, and the impact the guidance has for biotechnology and pharmaceutical companies performing sterile manufacturing process validation. |
DSM, the custom manufacturing business of Royal DSM, and the biopharmaceutical company Agennix have signed a new contract under which DSM will manufacture the oral dendritic cell mediated immunotherapy talactoferrin for Agennix at commercial levels in anticipation of positive Phase III clinical-data and product approval. DSM is currently manufacturing talactoferrin for use in ongoing clinical trials, including the Fortis-M trial in nonsmall cell lung cancer, and will continue to supply talactoferrin for clinical trials as well as to support a potential commercial launch. Read More
Advertisement:
Topical Semi-Solid Formulations: CMC Considerations for Stability, Analytical, and Safety Studies.
Live Webcast: Thursday, March 22, 2012 at 1:00 PM EST
Register Free at  http://pharmtech.com/formulations |
The Generic Pharmaceutical Association (GPhA) has pledged its support to the Pharmaceutical Traceability Enhancement Code (RxTEC), a new system for ensuring the security of the US pharmaceutical supply chain. The RxTEC model, which was developed by the Pharmaceutical Distribution Security Alliance, a multistakeholder initiative designed to increase patient access to safe medicines while improving the security of the American drug-distribution system. Read More
Advertisement:
Making Sense of Excipient Performance for Quality by Design (QbD)
Live Webcast: Thursday, April 19, 2012 at 10:00 EST, 15:00 GMT, 16:00 CET, 20:30 IST
Register Free at  http://www.pharmtech.com/excipient |
Industry Briefs:
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More
Do you have news to report on facility expansions, contracts, service agreements, mergers, acquisitions, or personnel appointments? Send press releases to ptpress@advanstar.com |
|
|
|
|
|
|
|
